<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "12: will continue", fill: "#ffe4e1"},
{source: "12: will continue", target: "12: incur research", fill: "#ffe4e1"},
{source: "12: incur research", target: "12: development", fill: "#ffe4e1"},
{source: "12: will continue", target: "16: profitability", fill: "#eedc82"},
{source: "16: profitability", target: "16: market value", fill: "#eedc82"},
{source: "16: market value", target: "16: common stock will decline", fill: "#eedc82"},
{source: "16: profitability", target: "17: relationship", fill: "#fefe33"},
{source: "17: relationship", target: "17: effectively", fill: "#fefe33"},
{source: "17: effectively", target: "17: commercialize effectively", fill: "#fefe33"},
{source: "17: commercialize effectively", target: "17: products based on", fill: "#fefe33"},
{source: "17: products based on", target: "17: technologies", fill: "#fefe33"},
{source: "17: relationship", target: "20: may terminate", fill: "#918151"},
{source: "20: may terminate", target: "20: agreement with", fill: "#918151"},
{source: "20: agreement with", target: "20: without reason at", fill: "#918151"},
{source: "20: without reason at", target: "20: by providing us with", fill: "#918151"},
{source: "20: may terminate", target: "21: also may terminate", fill: "#039"},
{source: "21: also may terminate", target: "21: agreement", fill: "#039"},
{source: "21: agreement", target: "21: competitor", fill: "#039"},
{source: "21: also may terminate", target: "22: addition while", fill: "#cd853f"},
{source: "22: addition while", target: "22: manufacturing", fill: "#cd853f"},
{source: "22: manufacturing", target: "22: operations", fill: "#cd853f"},
{source: "22: operations", target: "22: obligations", fill: "#cd853f"},
{source: "22: obligations", target: "22: functions under", fill: "#cd853f"},
{source: "22: functions under", target: "22: agreement", fill: "#cd853f"},
{source: "22: addition while", target: "24: If Veridex ", fill: "#aa98a9"},
{source: "24: If Veridex ", target: "24: obligations", fill: "#aa98a9"},
{source: "24: obligations", target: "24: agreement", fill: "#aa98a9"},
{source: "24: agreement", target: "24: deploy adequate resources", fill: "#aa98a9"},
{source: "24: deploy adequate resources", target: "24: commercialize", fill: "#aa98a9"},
{source: "24: commercialize", target: "24: would incur significant delays", fill: "#aa98a9"},
{source: "24: would incur significant delays", target: "24: commercialization", fill: "#aa98a9"},
{source: "24: commercialization", target: "24: enter into", fill: "#aa98a9"},
{source: "24: enter into", target: "24: agreement with", fill: "#aa98a9"},
{source: "24: agreement with", target: "24: company with", fill: "#aa98a9"},
{source: "24: company with", target: "24: functions on", fill: "#aa98a9"},
{source: "24: functions on", target: "24: functions successfully ourselves", fill: "#aa98a9"},
{source: "24: If Veridex ", target: "84: stockholders could", fill: "#480607"},
{source: "84: stockholders could", target: "84: new investors could", fill: "#480607"},
{source: "84: new investors could", target: "84: existing shareholders", fill: "#480607"},
{source: "84: stockholders could", target: "85: equity securities issued", fill: "#0abab5"},
{source: "85: equity securities issued", target: "85: also may provide", fill: "#0abab5"},
{source: "85: also may provide", target: "85: rights preferences", fill: "#0abab5"},
{source: "85: rights preferences", target: "85: privileges senior", fill: "#0abab5"},
{source: "85: privileges senior", target: "85: common stock", fill: "#0abab5"},
{source: "85: equity securities issued", target: "START_HERE", fill: "#0abab5"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Life Sciences Tools and Services</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_studies">Development studies</a></td>
      <td>Development studies is an interdisciplinary branch of social science. Development studies is offered as a specialized master's degree in a number of reputed universities around the world, such as the University of Cambridge, the London School of Economics and Political Science, King’s College London, the Institute of Development Studies at the University of Sussex, Oxford University, Harvard University, Balsillie School of International Affairs, Graduate Institute Geneva, Indian Institute of Technology Madras, SOAS London, Tata Institute of Social Sciences and University of Warwick, and less commonly, as an undergraduate degree, such as at the University of Sussex, University of Guelph, University of Toronto and McGill University.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_Development_Index">Human Development Index</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Paris_Agreement">Paris Agreement</a></td>
      <td>The Paris Agreement (French: Accord de Paris), often referred to as the Paris Accords or the Paris Climate Accords, is an international treaty on climate change, adopted in 2015. It covers climate change mitigation, adaptation, and finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-disclosure_agreement">Non-disclosure agreement</a></td>
      <td>A non-disclosure agreement (NDA), also known as a confidentiality agreement (CA), confidential disclosure agreement (CDA), proprietary information agreement (PIA), secrecy agreement (SA), or non-disparagement agreement, is a legal contract or part of a contract between at least two parties that outlines confidential material, knowledge, or information that the parties wish to share with one another for certain purposes, but wish to restrict access to. Doctor–patient confidentiality (physician–patient privilege), attorney–client privilege, priest–penitent privilege and bank–client confidentiality agreements are examples of NDAs, which are often not enshrined in a written contract between the parties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TRIPS_Agreement">TRIPS Agreement</a></td>
      <td>The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Haavara_Agreement">Haavara Agreement</a></td>
      <td>The Haavara Agreement (Hebrew: הֶסְכֵּם הַעֲבָרָה‎  Translit.: heskem haavara   Translated: "transfer agreement") was an agreement between Nazi Germany and Zionist German Jews signed on 25 August 1933. The agreement was finalized after three months of talks by the Zionist Federation of Germany, the Anglo-Palestine Bank (under the directive of the Jewish Agency) and the economic authorities of Nazi Germany.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Schengen_Agreement">Schengen Agreement</a></td>
      <td>The Schengen Agreement (English:  SHENG-ən, Luxembourgish: [ˈʃæŋən] (listen)) is a treaty which led to the creation of Europe's Schengen Area, in which internal border checks have largely been abolished. It was signed on 14 June 1985, near the town of Schengen, Luxembourg, by five of the ten member states of the then European Economic Community.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Simla_Agreement">Simla Agreement</a></td>
      <td>The Simla Agreement, also spelled Shimla Agreement, was a peace treaty signed between India and Pakistan on 2 July 1972 in Shimla, the capital city of the Indian state of Himachal Pradesh. It followed the Indo-Pakistani War of 1971, which began after India intervened in East Pakistan as an ally of Bengali rebels who were fighting against Pakistani state forces in the Bangladesh Liberation War.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Textile_manufacturing">Textile manufacturing</a></td>
      <td>Textile manufacturing is a major industry. It is largely based on the conversion of fibre into yarn, then yarn into fabric.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bally_Manufacturing">Bally Manufacturing</a></td>
      <td>Bally Manufacturing, later renamed Bally Entertainment, was an American company that began as a pinball and slot machine manufacturer, and later expanded into casinos, video games, health clubs, and theme parks. It was acquired by Hilton Hotels in 1996.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kendrick_Lamar">Kendrick Lamar</a></td>
      <td>Kendrick Lamar Duckworth (born June 17, 1987) is an American rapper, songwriter, and record producer. He is often cited as one of the most influential rappers of his generation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Windows_Notepad">Windows Notepad</a></td>
      <td>Windows Notepad is a simple text editor for Windows; it creates and edits plain text documents. First released in 1983 to commercialize the computer mouse in MS-DOS, Notepad has been part of every version of Windows ever since.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>IMMUNICON CORP      Item 1A    Risk factors          The following is a discussion of <font color="blue">certain <font color="blue">significant</font> risk factors</font> that could     <font color="blue"><font color="blue">potentially</font> negatively impact</font> our <font color="blue">financial condition</font>, performance and     prospects</td>
    </tr>
    <tr>
      <td>In addition to other information contained in this report, you     <font color="blue">should carefully</font> consider the <font color="blue">following factors</font> in evaluating our company</td>
    </tr>
    <tr>
      <td>Any of the <font color="blue">following factors</font> could materially and <font color="blue"><font color="blue">adversely</font> affect</font> our     business, <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>RISKS RELATING TO OUR BUSINESS          We  have  a  history  of operating losses, expect to continue to incur     substantial losses, and <font color="blue">might never</font> achieve or maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have incurred <font color="blue">significant</font> net losses     since  we began <font color="blue">operations</font> in 1983</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had an     accumulated deficit dlra118dtta4 million</td>
    </tr>
    <tr>
      <td>For the three years ended <font color="blue">December </font>31,     2005, 2004 and 2003 we had net losses of dlra26dtta9 million, dlra27dtta9 million and     dlra17dtta6 million, respectively</td>
    </tr>
    <tr>
      <td>These losses have resulted <font color="blue">primarily from costs</font>     incurred in our research and <font color="blue"><font color="blue">development</font> programs</font> and from our general and     <font color="blue"><font color="blue">administrative</font> expenses</font></td>
    </tr>
    <tr>
      <td>Because our operating <font color="blue">expenses may increase</font> in the     near  term, we will need to <font color="blue">generate <font color="blue">significant</font> <font color="blue">additional</font> revenue</font> to     achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>As we do not as yet have sufficient operating revenue     from the sales of our products to offset our losses, we do not expect to     have any sufficient operating <font color="blue">income from</font> the sale of our <font color="blue">products until at</font>     least 2008</td>
    </tr>
    <tr>
      <td>We <font color="blue">will continue</font> to <font color="blue">incur research</font> and <font color="blue">development</font> and clinical     trial expenses, as well as increased <font color="blue">manufacturing</font>, sales and marketing     expenses</td>
    </tr>
    <tr>
      <td>These losses, among other things, have had and <font color="blue">will continue</font> to     have  an  adverse  effect  on  our  working  capital, total assets and     <font color="blue">stockholders</font>’  equity</td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">numerous risks</font> and <font color="blue">uncertainties</font>     <font color="blue">associated with</font> our product <font color="blue">development</font> efforts,       _________________________________________________________________         34      ______________________________________________________________________       Part I      _________________________________________________________________         <font color="blue">market <font color="blue">acceptance</font></font> and <font color="blue">uncertainties</font> concerning the success of <font color="blue">sales efforts</font>     by us and Veridex, we are unable to predict when we <font color="blue">will become profitable</font>,     and we <font color="blue">may never become profitable</font></td>
    </tr>
    <tr>
      <td>Even if we do achieve <font color="blue">profitability</font>, we     may not be able to sustain or increase <font color="blue">profitability</font> on a quarterly or     <font color="blue">annual basis</font></td>
    </tr>
    <tr>
      <td>If we are unable to achieve and then maintain <font color="blue">profitability</font>,     the <font color="blue">market value</font> of our <font color="blue"><font color="blue">common stock</font> will decline</font></td>
    </tr>
    <tr>
      <td>If  our  <font color="blue">relationship</font>  with Veridex is terminated or does not function     <font color="blue">effectively</font>, we may be unable to continue to <font color="blue">commercialize</font> <font color="blue">effectively</font>     certain of our <font color="blue">products <font color="blue">based on</font></font> our <font color="blue">technologies</font> in the field of cancer</td>
    </tr>
    <tr>
      <td>We <font color="blue">entered into</font> a <font color="blue">development</font>, license and <font color="blue">supply <font color="blue"><font color="blue">agreement</font> with</font></font> Veridex,     under which we granted to Veridex a worldwide exclusive license in the field     of cancer to <font color="blue">commercialize</font> <font color="blue">cell analysis</font> <font color="blue">products <font color="blue">based on</font></font> our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also appointed</font> Veridex as our exclusive sales, invoicing and <font color="blue">collection</font>     agent for our <font color="blue"><font color="blue">cell analysis</font> instrumentation</font> in cancer</td>
    </tr>
    <tr>
      <td>Veridex <font color="blue">may terminate</font>     this <font color="blue"><font color="blue">agreement</font> with</font> or <font color="blue">without reason at</font> any time <font color="blue">by providing us with</font>     24 months’ prior written notice</td>
    </tr>
    <tr>
      <td>Veridex also <font color="blue">may terminate</font> this <font color="blue">agreement</font>     if we are in material breach or are acquired by a <font color="blue">competitor</font> in the IVD     field</td>
    </tr>
    <tr>
      <td>In addition, while we have granted Veridex the exclusive right to     market,  distribute and conduct field, technical, customer service and     certain <font color="blue">manufacturing</font> finishing <font color="blue">operations</font> for these products, Veridex has     very limited <font color="blue">obligations</font> to perform these <font color="blue">functions under</font> this <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>For example, the <font color="blue">agreement</font> does not require Veridex to meet any minimum     levels  with  respect to sales, <font color="blue">marketing personnel</font> or other marketing     <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td><font color="blue">If Veridex </font>were to terminate, or fail to meet its <font color="blue">obligations</font>     under this <font color="blue">agreement</font> or fail to <font color="blue">deploy adequate resources</font> to <font color="blue">commercialize</font>     products under this <font color="blue">agreement</font>:         Ø   we <font color="blue">would incur <font color="blue">significant</font> delays</font> and expense in the <font color="blue">commercialization</font>     of these products;         Ø   we might be unable to <font color="blue">enter into</font> a similar <font color="blue"><font color="blue">agreement</font> with</font> another     <font color="blue">company with</font> similar resources to <font color="blue">commercialize</font> these products and perform     these <font color="blue">functions on</font> acceptable terms, if at all; and         Ø   we might be unable to <font color="blue">commercialize</font> these products or perform these     <font color="blue">functions <font color="blue">successfully</font> ourselves</font></td>
    </tr>
    <tr>
      <td>Any of these outcomes could result in delays in our ability to generate     revenues from the sales of these products, an increase in our expenses and a     resulting <font color="blue">adverse impact on</font> our <font color="blue">operations</font> and financial results, and the     value of our <font color="blue"><font color="blue">common stock</font> would likely decline</font></td>
    </tr>
    <tr>
      <td>If we and Veridex are able to <font color="blue">generate product sales under</font> our <font color="blue">agreement</font>, we     are required to invest an amount ranging from between 8dtta5prca and 10prca of total     <font color="blue">net product sales by</font> Veridex, <font color="blue">excluding revenue from <font color="blue">cell analysis</font> system</font>     sales,  in  research  and <font color="blue">development</font> for cancer-related <font color="blue">cell analysis</font>     products</td>
    </tr>
    <tr>
      <td>If our products and Veridex’s products do not achieve <font color="blue">market <font color="blue">acceptance</font></font>, we     will be unable to <font color="blue">generate <font color="blue">significant</font> revenues from them</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">future commercial success</font> of our products and of Veridex’s products     <font color="blue">based on</font> our <font color="blue">technologies</font> will depend primarily on:         Ø   convincing research, reference and <font color="blue">clinical laboratories</font> to conduct     <font color="blue">validation studies using</font> these products and to offer these <font color="blue">products as</font>     <font color="blue">research tools</font> for <font color="blue">scientists</font> and <font color="blue">clinical investigators</font> and <font color="blue">as <font color="blue">diagnostic</font></font>     products to physicians, <font color="blue">laboratory</font> <font color="blue">professionals</font> and other medical     <font color="blue">practitioners</font>; and         Ø   <font color="blue">convincing physicians</font> to order tests for their patients, and <font color="blue">laboratory</font>     <font color="blue">professionals</font> and other medical <font color="blue">practitioners</font> to use our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>To  accomplish this, we and Veridex will need to <font color="blue">convince oncologists</font>,     primary  care physicians, surgeons, <font color="blue">laboratory</font> <font color="blue">professionals</font> and other     members of the medical and <font color="blue">bio<font color="blue">technology</font> communities</font> of the benefits of     these  products  through published papers, presentations at scientific     <font color="blue">conferences</font> and       _________________________________________________________________                                                                            35      ______________________________________________________________________       Part I      _________________________________________________________________         <font color="blue"><font color="blue">additional</font> <font color="blue">clinical trials</font></font></td>
    </tr>
    <tr>
      <td>If we and Veridex are not successful in these     efforts,  the  market  <font color="blue">acceptance</font> for these <font color="blue">products could</font> be limited</td>
    </tr>
    <tr>
      <td>Additionally, if ongoing or <font color="blue">future <font color="blue">clinical trials</font></font> result in unfavorable or     <font color="blue">inconsistent</font> results, these <font color="blue">products may</font> not achieve <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>Other factors that might influence <font color="blue">market <font color="blue">acceptance</font></font> of these products     include the following:         Ø   evidence of <font color="blue">clinical utility</font>;         Ø   ability to obtain sufficient third-party coverage or <font color="blue">reimbursement</font>;         Ø   convenience and ease of <font color="blue">administration</font>;         Ø   <font color="blue">availability</font> of <font color="blue">alternative</font> and <font color="blue">competing <font color="blue"><font color="blue">diagnostic</font> products</font></font>;         Ø   cost-<font color="blue">effectiveness</font>;         Ø   <font color="blue">effectiveness</font> of marketing, <font color="blue">distribution</font> and <font color="blue">pricing strategy</font>; and         Ø   <font color="blue">publicity concerning</font> these products or <font color="blue"><font color="blue">competitive</font> products</font></td>
    </tr>
    <tr>
      <td>If these products do not gain broad <font color="blue">market <font color="blue">acceptance</font></font>, our business will     suffer</td>
    </tr>
    <tr>
      <td>If we or Veridex are not able to obtain all of the <font color="blue"><font color="blue">regulatory</font> approvals</font> and     <font color="blue">clearances</font> required to <font color="blue">commercialize</font> our products, our business would be     <font color="blue"><font color="blue">significant</font>ly harmed</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">products <font color="blue">based on</font></font> our <font color="blue">technologies</font> are <font color="blue"><font color="blue">generally</font> regulated as medical</font>     devices  by  the  FDA  and  comparable agencies of other countries</td>
    </tr>
    <tr>
      <td>In     particular, FDA <font color="blue">regulations</font> govern, among other things, the <font color="blue">activities</font> that     we and Veridex perform, including product <font color="blue">development</font>, product testing,     product labeling, product storage, pre-market notification clearance (or     510(k)  clearance)  or  pre-market  approval  (or PMA), <font color="blue">manufacturing</font>,     <font color="blue">advertising</font>, promotion, product sales, reporting of <font color="blue">certain product failures</font>     and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>Most of the products that we plan to develop and <font color="blue">commercialize</font> in the US     will require either 510(k) clearance, or PMA <font color="blue">approval from</font> the FDA prior to     marketing</td>
    </tr>
    <tr>
      <td>The 510(k) clearance process usually takes from two to twelve     months from submission, but can take longer</td>
    </tr>
    <tr>
      <td>The PMA process is much more     costly, lengthy and uncertain and <font color="blue">generally</font> takes from one to two years or     <font color="blue">longer from submission</font></td>
    </tr>
    <tr>
      <td>All of the products that we or Veridex intend to submit for FDA clearance or     <font color="blue">approval will</font> be subject to substantial <font color="blue">restrictions</font>, including, among other     things, <font color="blue">restrictions</font> on the <font color="blue">indications</font> for which we and Veridex may market     these products, which could result in <font color="blue">lower revenues</font></td>
    </tr>
    <tr>
      <td>The marketing claims     we  and  <font color="blue">Veridex  </font>will be permitted to make in labeling or <font color="blue">advertising</font>     regarding our <font color="blue">cancer <font color="blue"><font color="blue">diagnostic</font> products</font></font>, if cleared or <font color="blue">approved by</font> the FDA,     will be limited to those specified in any clearance or approval</td>
    </tr>
    <tr>
      <td>We expect     that initially many of these <font color="blue">products will</font> be limited to <font color="blue">research use only</font></td>
    </tr>
    <tr>
      <td>In addition, both we and Veridex are subject to inspection and marketing     surveillance  by  the  FDA to determine our <font color="blue">compliance with</font> <font color="blue">regulatory</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>determines that we or Veridex have failed to comply     with these <font color="blue">requirements</font>, it can institute a wide variety of <font color="blue">enforcement</font>     actions, ranging from a <font color="blue">public warning letter</font> to more <font color="blue">severe sanctions</font>,     including:         Ø   fines, injunctions and <font color="blue">civil penalties</font>;         Ø   recall or seizure of our products or Veridex’s products;         Ø   operating <font color="blue">restrictions</font>, partial suspension or <font color="blue">total shutdown</font> of     production;         Ø   denial of requests for 510(k) <font color="blue">clearances</font> or PMAs of product <font color="blue">candidates</font>;         Ø   withdrawal of 510(k) <font color="blue">clearances</font> already granted;         Ø   <font color="blue">disgorgement</font> of profits; and         Ø   criminal <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>_________________________________________________________________         36      ______________________________________________________________________       Part I      _________________________________________________________________         Any of these <font color="blue">enforcement</font> actions could affect our ability or Veridex’s     ability to <font color="blue"><font color="blue">commercially</font> distribute</font> our products in the US and may also harm     our  ability  to  conduct the <font color="blue">clinical trials</font> <font color="blue">necessary</font> to support the     marketing, clearance or approval of these products</td>
    </tr>
    <tr>
      <td>If the third-party <font color="blue">manufacture</font>rs we rely on either refuse or are unable to     <font color="blue">successfully</font>  <font color="blue">manufacture</font> certain of our products, we may be unable to     <font color="blue">commercialize</font> these products</td>
    </tr>
    <tr>
      <td>We have limited commercial <font color="blue">manufacturing</font> experience and <font color="blue">cap<font color="blue">abilities</font></font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">currently assemble</font> or perform final assembly, test and release of the CTAII     and  CellTracks  AutoPrep  System,  <font color="blue">as well as bulk reagents</font> and other     associated  products  used with the CellTracks AutoPrep System, at our     <font color="blue"><font color="blue">facility</font> located</font> in Huntingdon Valley, Pennsylvania</td>
    </tr>
    <tr>
      <td>We currently have     adequate <font color="blue">manufacturing</font> capacity to meet anticipated demand for 2006 and     2007</td>
    </tr>
    <tr>
      <td>However, in order to meet anticipated demand thereafter, we will     likely have to expand our <font color="blue">manufacturing</font> processes and <font color="blue">facilities</font> or increase     our reliance on third-party <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>Under our <font color="blue"><font color="blue">agreement</font> with</font> Veridex,     we might be required to establish a third <font color="blue">manufacturing</font> <font color="blue">facility</font> or qualify     a contract <font color="blue">manufacture</font>r in the future</td>
    </tr>
    <tr>
      <td>We might encounter <font color="blue"><font color="blue">difficult</font>ies</font> in     expanding our <font color="blue">manufacturing</font> processes and <font color="blue">facilities</font> or in expanding our     <font color="blue">relationship</font>s with third-party <font color="blue">manufacture</font>rs and might be <font color="blue">unsuccessful</font> in     overcoming these <font color="blue"><font color="blue">difficult</font>ies</font></td>
    </tr>
    <tr>
      <td>In that event, our ability to <font color="blue">meet product</font>     <font color="blue">demand could</font> be impaired or delayed</td>
    </tr>
    <tr>
      <td>We  <font color="blue">face <font color="blue">additional</font> risks inherent</font> in operating a single <font color="blue">manufacturing</font>     <font color="blue">facility</font>  for  those products we <font color="blue">manufacture</font> ourselves</td>
    </tr>
    <tr>
      <td>We do not have     <font color="blue">alternative</font> production plans in place or <font color="blue">alternative</font> <font color="blue">facilities</font> available at     this time</td>
    </tr>
    <tr>
      <td>If there are <font color="blue">unforeseen shutdowns</font> to our <font color="blue">facility</font>, we will be     unable to <font color="blue">satisfy customer orders on</font> a <font color="blue"><font color="blue">timely basis</font> with respect</font> to these     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely currently</font> and intend to continue to <font color="blue">rely <font color="blue">significant</font>ly</font> in     the future on third-party <font color="blue">manufacture</font>rs to produce some of our products</td>
    </tr>
    <tr>
      <td>For     example, we are <font color="blue">dependent on</font> a small, private contract design, engineering     and <font color="blue">manufacturing</font> company, Astro Instrumentation, LLC, or Astro, for our     <font color="blue">CellTracks AutoPrep System </font>and for <font color="blue">certain <font color="blue">components</font></font> of the CTAII If Astro     <font color="blue">loses <font color="blue">key personnel</font></font> or <font color="blue">encounters financial</font> or other <font color="blue"><font color="blue">difficult</font>ies</font>, they may     be unable to continue to <font color="blue">manufacture</font> this system and <font color="blue">provide ongoing design</font>     and <font color="blue">engineering support</font> for <font color="blue">commercialization</font> and <font color="blue">future <font color="blue">enhancements</font></font> of     this system, and we may have <font color="blue"><font color="blue">difficult</font>y replacing them</font></td>
    </tr>
    <tr>
      <td>In addition, we     <font color="blue">currently use</font> a third-party <font color="blue">manufacture</font>r for our <font color="blue">CellSave Preservative Tube</font></td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">dependent on</font> these third-party <font color="blue">manufacture</font>rs to perform their     <font color="blue">obligations</font> in a timely and <font color="blue">effective manner</font> and in <font color="blue">compliance with</font> FDA and     other <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If these third-party <font color="blue">manufacture</font>rs fail to     perform their <font color="blue">obligations</font>, our <font color="blue"><font color="blue">competitive</font> position</font> and ability to generate     <font color="blue">revenue could</font> be <font color="blue"><font color="blue">adversely</font> affect</font>ed in a number of ways, including:         Ø   we might not be able to initiate or <font color="blue">continue <font color="blue">clinical trials</font> on products</font>     that are under <font color="blue">development</font>;         Ø   we might be delayed in <font color="blue">submitting <font color="blue">applications</font></font> for <font color="blue"><font color="blue">regulatory</font> approvals</font>     and <font color="blue">clearances</font> for products; and         Ø   we might not be able to <font color="blue">meet commercial demands</font> for any approved or     <font color="blue">cleared products</font></td>
    </tr>
    <tr>
      <td>Any failures in <font color="blue">manufacturing</font> these <font color="blue">products may</font> also result in a breach of     our <font color="blue"><font color="blue">agreement</font> with</font> Veridex</td>
    </tr>
    <tr>
      <td>If  third-party payors do not <font color="blue">reimburse customers</font> for our products and     Veridex’s  products,  they might not be used or purchased, which would     <font color="blue"><font color="blue">adversely</font> affect</font> our revenues</td>
    </tr>
    <tr>
      <td>The majority of the sales of our products and Veridex’s <font color="blue">products <font color="blue">based on</font></font>     our <font color="blue">technologies</font> in the US and other <font color="blue">markets will depend</font>, in large part, on     the <font color="blue">availability</font> of adequate <font color="blue">reimbursement</font> to users of these <font color="blue">products from</font>     <font color="blue">government insurance</font> plans, including Medicare and Medicaid in the US,     managed       _________________________________________________________________                                                                            37      ______________________________________________________________________       Part I      _________________________________________________________________         care organizations, private insurance plans and other third-party payors</td>
    </tr>
    <tr>
      <td>Because these products have <font color="blue">only recently been <font color="blue">commercially</font> introduced</font>,     third-party payors have limited history of <font color="blue">reimbursing</font> for the cost of these     products</td>
    </tr>
    <tr>
      <td>Third-party payors are often reluctant to <font color="blue">reimburse healthcare</font>     providers for the use of <font color="blue"><font color="blue">medical <font color="blue"><font color="blue">diagnostic</font> products</font></font> incorporating new</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition, third-party payors are increasingly limiting     <font color="blue">reimbursement</font>  coverage  for  <font color="blue">medical <font color="blue"><font color="blue">diagnostic</font> products</font></font> and, in many     instances, are <font color="blue">exerting pressure on medical products suppliers</font> to reduce     their  prices</td>
    </tr>
    <tr>
      <td>Consequently,  third-party  <font color="blue">reimbursement</font> might not be     <font color="blue">consistently available</font> or adequate to cover the cost of our products or     changes may occur in the <font color="blue">reimbursement</font> policies of third-party payors</td>
    </tr>
    <tr>
      <td>Any     of these events could limit our ability or Veridex’s ability to sell these     products or cause the prices of these products to be reduced, which would     <font color="blue"><font color="blue">adversely</font> affect</font> our operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>each  third-party  payor individually approves <font color="blue">reimbursement</font>,     obtaining these approvals is a time-consuming and <font color="blue">costly process</font> that will     require us and Veridex to provide scientific and clinical support for the     use of each of these products to each third-party payor separately with no     assurance that <font color="blue">approval will</font> be obtained</td>
    </tr>
    <tr>
      <td>This <font color="blue">process could delay</font> the     <font color="blue">market <font color="blue">acceptance</font></font> of <font color="blue">new products</font> and could have a negative effect on our     revenues and operating results</td>
    </tr>
    <tr>
      <td>If we or any of our third-party <font color="blue">manufacture</font>rs do not maintain <font color="blue">high standards</font>     of <font color="blue">manufacturing</font> in <font color="blue">accordance with</font> Quality System Regulations, our ability     to develop, and Veridex’s and our ability to <font color="blue">commercialize</font> our products,     could be delayed or curtailed</td>
    </tr>
    <tr>
      <td>We and any third-party <font color="blue">manufacture</font>rs on which we <font color="blue">currently rely</font> or will rely     in the future, including those we rely on to produce our CellTracks AutoPrep     System and <font color="blue">CellSave Preservative Tube</font>, <font color="blue">must continuously adhere</font> to the     current  good <font color="blue">manufacturing</font> practices, or cGMP, set forth in the FDA’s     Quality System Regulations, or QSR, and enforced by the FDA through its     <font color="blue">facilities</font> inspection program</td>
    </tr>
    <tr>
      <td>In <font color="blue">complying with</font> QSR, we and any of our     third-party <font color="blue">manufacture</font>rs must expend <font color="blue">significant</font> time, money and effort in     design and <font color="blue">development</font>, testing, production, record-keeping and quality     control to assure that our <font color="blue">products meet applicable <font color="blue">specifications</font></font> and other     <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The failure to <font color="blue">comply with</font> these <font color="blue">specifications</font> and     other <font color="blue">requirements</font> could result in an FDA <font color="blue">enforcement</font> action, including the     seizure  of  products  and shut down of production</td>
    </tr>
    <tr>
      <td>We or any of these     third-party  <font color="blue">manufacture</font>rs  also  may be subject to comparable or more     <font color="blue">stringent <font color="blue">regulations</font></font> of foreign <font color="blue">regulatory</font> authorities, which include     <font color="blue">compliance with</font> ISO 13485 2003 and the European Union’s in vitro Diagnostic     Directive 98/97/EC If we or any of our third-party <font color="blue">manufacture</font>rs fail to     <font color="blue">comply with</font> these <font color="blue">regulations</font>, we might be subject to <font color="blue">regulatory</font> action,     <font color="blue">which could delay</font> or curtail our ability to develop, and Veridex’s and our     ability to <font color="blue">commercialize</font>, <font color="blue">products <font color="blue">based on</font></font> our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain <font color="blue">necessary</font> funds for our <font color="blue">operations</font>, we will be unable     to continue to develop and <font color="blue">commercialize</font> <font color="blue">new products</font> and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We expect <font color="blue">capital outlays</font> and operating <font color="blue">expenditures</font> to <font color="blue">increase over</font> the     <font color="blue">next several years as</font> we expand our infrastructure, <font color="blue">commercialization</font>,     <font color="blue">manufacturing</font>, <font color="blue">clinical trials</font> and research and <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Specifically, we will need to <font color="blue">raise <font color="blue">additional</font> capital</font> to, among other     things:         Ø   sustain <font color="blue">commercialization</font> with Veridex of our initial products;         Ø   pursue <font color="blue"><font color="blue">regulatory</font> approvals</font> and <font color="blue">clearances</font>;         Ø   expand our <font color="blue">technologies</font> into other areas of cancer and medicine;         Ø   expand our research and <font color="blue">development</font> <font color="blue">activities</font>;         Ø   acquire or license <font color="blue">technologies</font>;       _________________________________________________________________         38      ______________________________________________________________________       Part I      _________________________________________________________________         Ø   fund our clinical trial <font color="blue">activities</font>;         Ø   expand our <font color="blue">manufacturing</font> <font color="blue">activities</font>; and         Ø   finance capital <font color="blue">expenditures</font> and our general and <font color="blue">administrative</font>     expenses</td>
    </tr>
    <tr>
      <td>To date, we have raised capital through private equity, public equity and     debt   <font color="blue">financings</font>,  license  and  milestone  revenues  from  corporate     <font color="blue">collaborations</font>, capital equipment and leasehold financing, government grants     and <font color="blue">interest earned on cash</font> and <font color="blue"><font color="blue">investment</font>s</font></td>
    </tr>
    <tr>
      <td>However, our present and future     funding <font color="blue">requirements</font> will depend on many factors, including, among other     things:         Ø   the level of research and <font color="blue">development</font> <font color="blue">investment</font> required to maintain     and improve our <font color="blue">technology</font> position;         Ø   costs of filing, prosecuting, defending and <font color="blue">enforcing patent</font> claims and     other <font color="blue"><font color="blue">intellectual</font> property rights</font>;         Ø   our need or decision to acquire or license complementary <font color="blue">technologies</font> or     acquire <font color="blue">complementary businesses</font>;         Ø   changes in product <font color="blue">development</font> plans needed to address any <font color="blue"><font color="blue">difficult</font>ies</font>     in <font color="blue">manufacturing</font> or <font color="blue">commercialization</font>;         Ø   <font color="blue">competing <font color="blue">technological</font></font> and market <font color="blue">development</font>s; and         Ø   changes in <font color="blue">regulatory</font> policies or laws that affect our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  do  not  know  whether  <font color="blue">additional</font>  <font color="blue">financing will</font> be <font color="blue">available on</font>     <font color="blue">commercially</font> acceptable terms when needed, if at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are     not available or are not <font color="blue">available on</font> <font color="blue">commercially</font> acceptable terms, our     ability  to  fund  our <font color="blue">operations</font>, develop products or <font color="blue">technologies</font> or     otherwise respond to <font color="blue"><font color="blue">competitive</font> pressures could</font> be <font color="blue"><font color="blue">significant</font>ly delayed</font> or     limited, and we might need to downsize or halt our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we raise <font color="blue">additional</font> funds by issuing equity securities, further dilution     to  our <font color="blue">stockholders</font> could result, and <font color="blue">new investors could</font> have rights     superior to those of our <font color="blue">existing shareholders</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">equity securities issued</font>     <font color="blue">also may provide</font> for rights, preferences or <font color="blue">privileges senior</font> to those of     holders of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we raise <font color="blue">additional</font> funds by issuing debt     securities,  these  <font color="blue">debt securities would</font> have rights, preferences and     <font color="blue">privileges senior</font> to those of holders of our <font color="blue">common stock</font>, and the terms of     the debt securities issued could impose <font color="blue">significant</font> <font color="blue">restrictions</font> on our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If  we  raise <font color="blue">additional</font> funds through <font color="blue">collaborations</font> and     <font color="blue">licensing arrangements</font>, we might be required to <font color="blue">relinquish <font color="blue">significant</font></font>     rights to our <font color="blue">technologies</font> or products, or <font color="blue">grant licenses on terms</font> that are     not favorable to us</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available, we may have to     delay or may be unable to continue to develop our products</td>
    </tr>
    <tr>
      <td>If the <font color="blue">third parties</font> with which we intend to contract with for clinical     trials do not perform in an acceptable manner, or if we <font color="blue">suffer setbacks</font> in     these <font color="blue">clinical trials</font>, our business may suffer</td>
    </tr>
    <tr>
      <td>We do not have the ability to <font color="blue">conduct independently</font> the <font color="blue">clinical trials</font>     required to obtain <font color="blue">regulatory</font> <font color="blue">clearances</font> for our products</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot locate</font> and <font color="blue">enter into</font> favorable <font color="blue">agreement</font>s with     acceptable <font color="blue">third parties</font>, or if these <font color="blue">third parties</font> do not <font color="blue">successfully</font>     carry out their contractual <font color="blue">obligations</font>, meet expected <font color="blue">deadlines</font> or follow     <font color="blue">regulatory</font> <font color="blue">requirements</font>, including clinical <font color="blue">laboratory</font>, <font color="blue">manufacturing</font> and     good  clinical  practice  guidelines, then we may be the subject of an     <font color="blue">enforcement</font> action by the FDA or some other <font color="blue">regulatory</font> body, and may be     unable to obtain <font color="blue">clearances</font> for our products or to <font color="blue">commercialize</font> them on a     <font color="blue">timely basis</font>, if at all</td>
    </tr>
    <tr>
      <td>_________________________________________________________________                                                                            39      ______________________________________________________________________       Part I      _________________________________________________________________         The <font color="blue">completion</font> of <font color="blue">clinical trials</font> of our <font color="blue">products may</font> be <font color="blue">delayed by</font> many     other factors, including the rate of <font color="blue">enrollment</font> of patients</td>
    </tr>
    <tr>
      <td>Neither we nor     any third-party <font color="blue">clinical investigators</font> and CROs can control the rate of     patient  <font color="blue">enrollment</font>,  and  this  rate might not be <font color="blue">consistent with</font> our     <font color="blue">expectations</font> or sufficient to enable <font color="blue">clinical trials</font> of our products to be     completed  in  a <font color="blue">timely manner</font> or to be completed at all</td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">regulatory</font> authorities might not <font color="blue">permit us</font> to undertake <font color="blue">additional</font> clinical     trials for one or more of these products</td>
    </tr>
    <tr>
      <td>Currently, we have <font color="blue">two important</font>     <font color="blue">labeling trials underway</font> in colorectal and <font color="blue">prostate cancer</font></td>
    </tr>
    <tr>
      <td>If we suffer any     <font color="blue">significant</font> delays, setbacks or negative results in, or <font color="blue">termination</font> of,     these <font color="blue">clinical trials</font> or our other <font color="blue">clinical trials</font> for our products, we may     be unable to <font color="blue">generate product sales from</font> these products in the future</td>
    </tr>
    <tr>
      <td>If we <font color="blue">lose key <font color="blue">management</font></font> or <font color="blue">scientific personnel</font>, scientific <font color="blue"><font color="blue">collaborator</font>s</font>     or other advisors, our business <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font>, in large part, on the efforts and <font color="blue">abilities</font> of Byron D     Hewett,  who is our President and Chief Executive Officer, Leon WMM     Terstappen, who is our <font color="blue">Senior Vice President of Research and Development </font>and     Chief  Scientific Officer, and James G Murphy, who is our Senior Vice     President of Finance and Administration and Chief Financial Officer, as well     as  the  other members of our <font color="blue">senior <font color="blue">management</font></font> and our scientific and     <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>Erickson notified our board of     <font color="blue">directors</font>  of his intention to step down as <font color="blue">Chief Executive Officer </font>on     March 31, 2006</td>
    </tr>
    <tr>
      <td>Given that the pool of individuals with relevant experience     in bio<font color="blue">technology</font> and <font color="blue"><font color="blue">diagnostic</font> products</font> in particular is limited, it would     be costly and time-consuming to replace any of our <font color="blue">senior <font color="blue">management</font></font> or     <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td>Although we maintain key-person life insurance on     Dr</td>
    </tr>
    <tr>
      <td>Terstappen, we do not maintain key-person life insurance on any of our     other officers, employees or <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also depend on</font> our scientific     <font color="blue"><font color="blue">collaborator</font>s</font> and other advisors, <font color="blue">particularly</font> with respect to our research     and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>If we lose the services of one or more of our key     officers, employees or <font color="blue">consultants</font>, or are unable to retain the services of     our  scientific  <font color="blue"><font color="blue">collaborator</font>s</font>  and  other  advisors, our research and     <font color="blue">development</font> and product <font color="blue">development</font> efforts could be delayed or curtailed</td>
    </tr>
    <tr>
      <td><font color="blue">If Veridex </font>and the other third-parties on which we <font color="blue">currently rely</font> or may     rely in the future to perform marketing, sales and <font color="blue">distribution</font> services for     our products do not <font color="blue">successfully</font> perform these services, our business will     be harmed</td>
    </tr>
    <tr>
      <td>We  have  limited  marketing,  sales  and  <font color="blue">distribution</font> experience and     <font color="blue">cap<font color="blue">abilities</font></font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">commercialize</font> any of our products, we must either     <font color="blue">internally</font> develop sales, marketing and <font color="blue">distribution</font> <font color="blue">cap<font color="blue">abilities</font></font> or make     arrangements with <font color="blue">third parties</font> to perform these services</td>
    </tr>
    <tr>
      <td>We currently     rely, and we intend to rely for the <font color="blue">foreseeable future</font> on sales, marketing     and <font color="blue">distribution</font> arrangements with <font color="blue">third parties</font> for the <font color="blue">commercialization</font>     of our products</td>
    </tr>
    <tr>
      <td>Specifically, we rely on Veridex for the <font color="blue">commercialization</font>     of <font color="blue">cancer <font color="blue">diagnostic</font></font> <font color="blue">products <font color="blue">based on</font></font> our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We may be unable to     <font color="blue">enter into</font> sales, marketing and <font color="blue">distribution</font> <font color="blue">agreement</font>s with <font color="blue">third parties</font>     on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>Also, the sales, marketing, and <font color="blue">distribution</font>     efforts of these <font color="blue">third parties</font> might not be successful</td>
    </tr>
    <tr>
      <td>Any <font color="blue">sales through</font>     these <font color="blue">third parties</font> might be <font color="blue">less profitable</font> to <font color="blue">us than <font color="blue">direct sales</font></font></td>
    </tr>
    <tr>
      <td>If we decide to perform any sales, marketing and <font color="blue">distribution</font> functions     ourselves, we might face a number of risks, including:         Ø   the <font color="blue">inability</font> to attract and build the <font color="blue">significant</font> and <font color="blue">skilled marketing</font>     staff or sales force <font color="blue">necessary</font> to <font color="blue">commercialize</font> and gain <font color="blue">market <font color="blue">acceptance</font></font>     for our products;         Ø   the amount of time and cost of <font color="blue">establishing</font> a <font color="blue">marketing staff</font> or sales     <font color="blue">force might</font> not be <font color="blue">justifiable by</font> the <font color="blue">revenues generated by</font> any particular     product; and         Ø   the failure of our <font color="blue">direct sales</font> and <font color="blue">marketing personnel</font> to initiate and     execute successful <font color="blue">commercialization</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>_________________________________________________________________         40      ______________________________________________________________________       Part I      _________________________________________________________________         If the limited number of suppliers on which we rely fail to supply the raw     materials we use in the <font color="blue">manufacturing</font> of our <font color="blue">reagent products</font>, we might be     unable  to  satisfy  product demand, which would negatively impact our     business</td>
    </tr>
    <tr>
      <td>Some of the <font color="blue"><font color="blue">raw materials</font> used</font> in the <font color="blue">manufacturing</font> of our <font color="blue">reagent products</font>     used in several of our platforms and <font color="blue">instruments currently</font> are available     only  from  a limited number of suppliers</td>
    </tr>
    <tr>
      <td>We acquire all of these raw     <font color="blue">materials on</font> a purchase-order basis, which means that the supplier is not     required to <font color="blue">supply us with specified quantities</font> of these <font color="blue"><font color="blue">raw materials</font> over</font>     a <font color="blue">certain period</font> of time or to set aside part of its inventory for our     forecasted <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Additionally, for certain of these <font color="blue">raw materials</font>,     we have not arranged for <font color="blue">alternative</font> suppliers, and it might be <font color="blue">difficult</font> to     find <font color="blue">alternative</font> suppliers in a <font color="blue">timely manner</font> and on terms acceptable to us</td>
    </tr>
    <tr>
      <td>Consequently, as we continue our <font color="blue">commercialization</font> efforts, if we do not     <font color="blue">forecast properly</font>, or if our suppliers are unable or unwilling to supply us     in <font color="blue">sufficient quantities</font> or on <font color="blue">commercially</font> acceptable terms, we might not     have access to <font color="blue">sufficient quantities</font> of these raw <font color="blue">materials on</font> a timely     basis and might not be able to <font color="blue">satisfy product demand</font></td>
    </tr>
    <tr>
      <td>In addition, if any of these <font color="blue">components</font> and <font color="blue">raw materials</font> are no longer     available in the marketplace, we will be forced to further develop our     <font color="blue">technologies</font> to <font color="blue">incorporate</font> alternate <font color="blue">components</font> and to do so in compliance     with QSR and other quality standards, such as ISO 13485</td>
    </tr>
    <tr>
      <td>If we <font color="blue">incorporate</font>     new <font color="blue">components</font> or <font color="blue">raw materials</font> into our products we might need to seek and     obtain <font color="blue">additional</font> approvals or <font color="blue">clearances</font> from the FDA or foreign <font color="blue">regulatory</font>     agencies, <font color="blue">which could delay</font> the <font color="blue">commercialization</font> of these products</td>
    </tr>
    <tr>
      <td>If  our  <font color="blue">competitor</font>s  develop  and market <font color="blue">technologies</font> or research and     <font color="blue"><font color="blue">diagnostic</font> products</font> faster than we or Veridex do or if those products are     more <font color="blue">effective than</font> our products, our <font color="blue">commercial opportunities will</font> be     reduced or eliminated</td>
    </tr>
    <tr>
      <td>The extent to which any of our <font color="blue">technologies</font> and products achieve market     <font color="blue">acceptance</font> will depend on many <font color="blue"><font color="blue">competitive</font> factors</font>, many of which are beyond     our control</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in the <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> industries,     and the <font color="blue">medical devices</font> and <font color="blue"><font color="blue">diagnostic</font> products</font> segments in particular, is     intense  and  has  <font color="blue">been accentuated by</font> the rapid pace of <font color="blue">technological</font>     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitor</font>s include large <font color="blue"><font color="blue">diagnostic</font>s</font> and <font color="blue">life sciences</font>     companies</td>
    </tr>
    <tr>
      <td>Most of these entities have <font color="blue">substantially</font> greater research and     <font color="blue">development</font>  <font color="blue">cap<font color="blue">abilities</font></font>  and  financial,  scientific, <font color="blue">manufacturing</font>,     marketing, sales and service resources than we do</td>
    </tr>
    <tr>
      <td>Some of them also have     more experience than we do in research and <font color="blue">development</font>, <font color="blue">clinical trials</font>,     <font color="blue">regulatory</font> matters, <font color="blue">manufacturing</font>, marketing and sales</td>
    </tr>
    <tr>
      <td>These organizations     <font color="blue">also <font color="blue">compete with</font> us</font> to:         Ø   pursue acquisitions, <font color="blue">joint ventures</font> or other <font color="blue">collaborations</font>;         Ø   license <font color="blue">proprietary</font> <font color="blue">technologies</font> that are <font color="blue"><font color="blue">competitive</font> with</font> our     <font color="blue">technologies</font>;         Ø   attract funding; and         Ø   attract and <font color="blue">hire scientific talent</font></td>
    </tr>
    <tr>
      <td>If we or Veridex cannot <font color="blue">successfully</font> <font color="blue">compete with</font> new or <font color="blue">existing products</font>     or <font color="blue">technologies</font>, sales of our <font color="blue">products will</font> suffer and we may never achieve     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Because of their greater experience with <font color="blue">commercializing</font>     their <font color="blue">technologies</font> and larger research and <font color="blue">development</font> <font color="blue">cap<font color="blue">abilities</font></font>, our     <font color="blue">competitor</font>s might succeed in developing and <font color="blue">commercializing</font> <font color="blue">technologies</font> or     products earlier and obtaining <font color="blue"><font color="blue">regulatory</font> approvals</font> and <font color="blue">clearances</font> from the     FDA more <font color="blue">rapidly than</font> Veridex or us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitor</font>s also might develop more     effective <font color="blue">technologies</font> or products that are more predictive, more highly     automated or more cost-effective, which may render our <font color="blue">technologies</font> or     <font color="blue">products obsolete</font> or non-<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>_________________________________________________________________                                                                            41      ______________________________________________________________________       Part I      _________________________________________________________________         If we experience delays in the <font color="blue">development</font> of <font color="blue">new products</font> or delays in     planned <font color="blue">improvements</font> to our products, our <font color="blue">commercial opportunities will</font> be     reduced</td>
    </tr>
    <tr>
      <td>To improve our <font color="blue"><font color="blue">competitive</font> position</font>, we believe that we will need to develop     new <font color="blue">products as</font> well as improve our <font color="blue">existing instruments</font> and software,     reagents  and  <font color="blue">ancillary</font>  products</td>
    </tr>
    <tr>
      <td><font color="blue">Improvements </font>in operator workflow,     automation and <font color="blue">throughput</font> (the number of tests that can be performed in a     <font color="blue">specified period</font> of time) for our <font color="blue">products will</font> be important to maintain a     <font color="blue"><font color="blue">competitive</font> position</font> of our <font color="blue">products as</font> we market to a broader, perhaps less     <font color="blue">technically proficient</font>, group of customers</td>
    </tr>
    <tr>
      <td>Our ability to develop new     products  and  make  <font color="blue">improvements</font>  in  our <font color="blue">products may</font> face <font color="blue">difficult</font>     <font color="blue">technological</font> challenges leading to <font color="blue">development</font> delays</td>
    </tr>
    <tr>
      <td>For example, we had     experienced delays in <font color="blue">connection with</font> the <font color="blue">development</font> of our laser-based     <font color="blue">CellTracks Analyzer </font><font color="blue">cell analysis</font> instrument for use in <font color="blue">cancer <font color="blue">diagnostic</font></font>     testing</td>
    </tr>
    <tr>
      <td>These delays were the result of technical problems <font color="blue">associated with</font>     <font color="blue">reliability</font> of the system to detect <font color="blue">cancer cells</font></td>
    </tr>
    <tr>
      <td>In response, in June 2005,     we introduced a <font color="blue">second generation</font> instrument, the <font color="blue">CellTracks Analyzer </font>II,     which, among other <font color="blue">improvements</font> over our current CellSpotter Analyzer,     <font color="blue">implements <font color="blue">enhancements</font> such as</font> the automation of <font color="blue">data acquisition</font> and     <font color="blue">enhanced <font color="blue">detection</font></font> of CTCs and other types of cells</td>
    </tr>
    <tr>
      <td>We are <font color="blue">also continuing</font>     to develop our <font color="blue">analyzer platforms further</font> because we believe that some of     the planned features, <font color="blue">such as foreign language capability</font> of our software     and the ability to <font color="blue">quantify cellular markers using</font> ASRs, may be required to     remain  <font color="blue">competitive</font> and <font color="blue">address future potential research</font> and clinical     <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font> complete <font color="blue">development</font> of new     products or planned <font color="blue">enhancements</font> to our products, in <font color="blue">each case without</font>     <font color="blue">significant</font>  delays,  our future <font color="blue"><font color="blue">competitive</font> position</font> may be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>If <font color="blue">product liability lawsuits</font> are <font color="blue">successfully</font> <font color="blue">brought against us</font>, we might     incur  substantial  li<font color="blue">abilities</font>  and  could  be  required to limit the     <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>Our  business <font color="blue">exposes us</font> to <font color="blue">potential product liability risks</font> that are     inherent in the testing, <font color="blue">manufacturing</font>, marketing and sale of <font color="blue">diagnostic</font>     products</td>
    </tr>
    <tr>
      <td>We might be unable to <font color="blue">avoid product liability</font> claims</td>
    </tr>
    <tr>
      <td><font color="blue">Product     </font>liability insurance <font color="blue">generally</font> is expensive for our industry</td>
    </tr>
    <tr>
      <td>If we are     unable to maintain <font color="blue">sufficient <font color="blue">insurance coverage</font> on reasonable terms</font> or to     <font color="blue">otherwise protect against potential product liability</font> claims, we may be     unable to <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>A <font color="blue">successful product liability</font> claim     <font color="blue">brought against us</font> in excess of any <font color="blue">insurance coverage</font> we have at that time     could cause us to incur substantial li<font color="blue">abilities</font> and our business to fail</td>
    </tr>
    <tr>
      <td>If we <font color="blue">use biological</font> and <font color="blue">hazardous materials</font> in a manner that causes injury,     we could be liable for damages</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> <font color="blue">activities</font> sometimes involve the <font color="blue">controlled use</font>     of  <font color="blue">potentially</font>  harmful biological materials, <font color="blue">hazardous materials</font> and     <font color="blue">chemicals</font></td>
    </tr>
    <tr>
      <td>We  cannot  <font color="blue">completely</font>  eliminate  the  risk of <font color="blue">accidental</font>     <font color="blue">contamination</font> or injury to <font color="blue">third parties</font> from the use, storage, handling or     disposal of these materials</td>
    </tr>
    <tr>
      <td>In the event of <font color="blue">contamination</font> or injury, we     could be held liable for any resulting damages, and any <font color="blue">liability could</font>     exceed our resources or any applicable <font color="blue">insurance coverage</font> we may have</td>
    </tr>
    <tr>
      <td>Additionally, we are subject on an <font color="blue">ongoing basis</font> to federal, state and local     laws and <font color="blue">regulations</font> governing the use, storage, handling and disposal of     these materials and <font color="blue">specified waste products</font></td>
    </tr>
    <tr>
      <td>The cost of <font color="blue">compliance with</font>     these laws and <font color="blue">regulations</font> might be <font color="blue">significant</font> and <font color="blue">could negatively affect</font>     our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">manage growth</font> in <font color="blue">connection with</font> our <font color="blue">transition from</font> an     early-stage <font color="blue">development</font> company to a company that <font color="blue">commercialize</font>s research     and <font color="blue"><font color="blue">diagnostic</font> products</font>, our <font color="blue">operations</font> will suffer</td>
    </tr>
    <tr>
      <td>We may need to add a <font color="blue">significant</font> number of <font color="blue">new personnel</font> and expand our     <font color="blue">cap<font color="blue">abilities</font></font> in order to <font color="blue">successfully</font> pursue our <font color="blue">commercialization</font> strategy     for our initial IVD <font color="blue">products as</font> well as our research       _________________________________________________________________         42      ______________________________________________________________________       Part I      _________________________________________________________________         and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>Certain aspects of our <font color="blue">operations</font> may need to be     <font color="blue">scaled up</font>, for example, to increase the <font color="blue">batch sizes</font> of <font color="blue">antibodies</font> and other     bulk  <font color="blue">components</font> that we will need to provide for use in the test kits     <font color="blue">manufacture</font>d  by  <font color="blue">Veridex  </font>and the number of instrument systems we can     <font color="blue">manufacture</font> per quarter</td>
    </tr>
    <tr>
      <td><font color="blue">Organizational </font>growth and scale-up of <font color="blue">operations</font>     could strain our existing managerial, operational, financial and other     resources</td>
    </tr>
    <tr>
      <td>If we fail to manage this growth <font color="blue">effectively</font>, we may not be able     to achieve our research and <font color="blue">development</font> and <font color="blue">commercialization</font> goals</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OUR INTELLECTUAL PROPERTY          If we are unable to protect our <font color="blue"><font color="blue">proprietary</font> rights</font>, we may not be able to     compete <font color="blue">effectively</font></td>
    </tr>
    <tr>
      <td>We have obtained patents in the US and in <font color="blue">foreign countries</font> relating to many     of the <font color="blue">technologies</font> that are the basis of our products, such as the basic     <font color="blue">technologies</font> relating to the <font color="blue">separation</font> and isolation of cells for the     <font color="blue">detection</font> of cancer and the <font color="blue">various aspects</font> of the reagents, methods and     instrument platforms that we are <font color="blue">commercializing</font> or plan to <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td>In addition, we maintain <font color="blue">trade secrets</font>, especially where we believe patent     protection is not <font color="blue">appropriate</font> or obtainable, on <font color="blue">various aspects</font> of our     <font color="blue">technologies</font> and that we do not wish to <font color="blue">become publicly known</font></td>
    </tr>
    <tr>
      <td>However,     obtaining,  defending and enforcing our patents and other <font color="blue">intellectual</font>     <font color="blue">property rights involve complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>For example,     many  of  our  key  patents relating to our basic <font color="blue">technologies</font> for the     <font color="blue">separation</font> and isolation of cells for the <font color="blue">detection</font> of <font color="blue">cancer contain</font> claims     covering our processes for <font color="blue">manufacturing</font> and using our magnetic <font color="blue">separation</font>     particles, or <font color="blue">ferrofluids</font></td>
    </tr>
    <tr>
      <td>If a <font color="blue">competitor</font> were to practice or use these     processes  without  our  knowledge  or  consent,  these <font color="blue">patents may</font> be     <font color="blue">particularly</font> <font color="blue">difficult</font> to defend or enforce because it may not be apparent     from <font color="blue">examination</font> of the <font color="blue">competitor</font>’s products that the <font color="blue">competitor</font> is using     our <font color="blue">patented processes</font></td>
    </tr>
    <tr>
      <td>In particular, if we were not able <font color="blue">successfully</font> to     defend or enforce our patents that cover our <font color="blue">ferrofluids</font>, which are utilized     as a key component of our CellTracks AutoPrep System, <font color="blue">competitor</font>s could more     easily produce systems that might be able to perform <font color="blue">separation</font> of CTCs from     blood  samples  in a manner <font color="blue">substantially</font> equivalent to our CellTracks     AutoPrep System <font color="blue">without compensating us</font>, resulting in substantial damage to     our business</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>the issuance of a patent is not <font color="blue">conclusive</font> of its validity or     <font color="blue">enforceability</font> and can be challenged, we do not know how much protection, if     any, our <font color="blue">patents will provide</font> to us if we attempt to <font color="blue">enforce them</font> or if     <font color="blue">others challenge</font> their validity or <font color="blue">enforceability</font> in court</td>
    </tr>
    <tr>
      <td>For example, if     our patents relating to the <font color="blue">separation</font> of CTCs <font color="blue">from blood samples</font> were     challenged and invalidated, we would not be able to <font color="blue">prevent others from</font>     utilizing these <font color="blue">key aspects</font> of our <font color="blue">technologies</font>, which would <font color="blue">substantially</font>     harm our business</td>
    </tr>
    <tr>
      <td>Moreover, our patent <font color="blue">applications</font> may not result in     <font color="blue">issued patents</font>, and even if issued, our <font color="blue">patents may</font> not contain claims that     are <font color="blue">sufficiently broad</font> to <font color="blue">prevent others from</font> practicing our <font color="blue">technologies</font> or     developing <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td>Accordingly, we <font color="blue">cannot assure</font> you that we     will be able to obtain, defend or enforce our <font color="blue"><font color="blue">patent rights</font> covering</font> our     <font color="blue">technologies</font> in the US or in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>In addition, if others     discover or mis<font color="blue">appropriate</font> the <font color="blue">technologies</font> that we have chosen to maintain     as  trade  secrets,  we  may  not  be able to <font color="blue">effectively</font> maintain our     <font color="blue">technologies</font> as <font color="blue">unpatented <font color="blue">trade secrets</font></font></td>
    </tr>
    <tr>
      <td>Although we have <font color="blue">taken measures</font> to     protect our <font color="blue">unpatented <font color="blue">trade secrets</font></font> and other non-public information such     as know-how, including the use of <font color="blue">confidentiality</font> and <font color="blue">invention assignment</font>     <font color="blue">agreement</font>s with our employees, <font color="blue">consultants</font> and some of our <font color="blue">contractors</font>, it     is possible that these <font color="blue">persons may unintentionally</font> or <font color="blue">willingly breach</font> the     <font color="blue">agreement</font>s or that our <font color="blue">competitor</font>s may independently develop or otherwise     discover our <font color="blue">trade secrets</font> and know-how</td>
    </tr>
    <tr>
      <td>A challenge to one or more of our pending patent <font color="blue">applications</font>, or issued     patents,  may result in limiting the coverage of our patents so that a     <font color="blue">competitor</font> can <font color="blue">effectively</font> avoid our patent claims</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">competitor</font>s     may avoid our patents by using <font color="blue">technologies</font> that perform in <font color="blue">substantially</font>     the <font color="blue">same manner as</font> our <font color="blue">technologies</font>, but avoid infringing our patent claims</td>
    </tr>
    <tr>
      <td>For example, if a <font color="blue">competitor</font> were to use a       _________________________________________________________________                                                                            43      ______________________________________________________________________       Part I      _________________________________________________________________         cell <font color="blue">separation</font> <font color="blue">technology</font> that performs as well, or nearly as well, as our     patented <font color="blue">ferrofluids</font>, the <font color="blue">competitor</font> may be able to <font color="blue">market products</font> that may     be <font color="blue">functionally equivalent</font> and perform as well or <font color="blue">nearly as well as</font> our     products, thereby diminishing the <font color="blue">competitive</font> advantage afforded by our     <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>Although we <font color="blue">may initiate <font color="blue">litigation</font></font> to stop the <font color="blue">infringement</font> of our patent     claims  or  to  attempt  to force an <font color="blue">unauthorized user</font> of our patented     <font color="blue">inventions</font>  or  <font color="blue">trade secrets</font> to <font color="blue">compensate us</font> for the <font color="blue">infringement</font> or     unauthorized use, patent and <font color="blue">trade secret <font color="blue">litigation</font></font> is complex and often     <font color="blue">difficult</font> and expensive, and <font color="blue">would consume</font> the time of our <font color="blue">management</font> and     other <font color="blue">significant</font> resources</td>
    </tr>
    <tr>
      <td>If the outcome of <font color="blue">litigation</font> is adverse to us,     <font color="blue">third parties</font> may be able to use our <font color="blue">technologies</font> without payments to us</td>
    </tr>
    <tr>
      <td>Moreover, some of our <font color="blue">competitor</font>s may be <font color="blue">better able</font> to sustain the costs of     <font color="blue">litigation</font> because they have <font color="blue">substantially</font> greater resources</td>
    </tr>
    <tr>
      <td>Because of     these  factors relating to <font color="blue">litigation</font>, we may be unable <font color="blue">effectively</font> to     prevent <font color="blue">misappropriation</font> of our patent and other <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>If the use of our <font color="blue">technologies</font> conflicts with the <font color="blue">intellectual</font> property     rights of third-parties, we may incur substantial li<font color="blue">abilities</font> and we may be     unable to <font color="blue">commercialize</font> <font color="blue">products <font color="blue">based on</font></font> these <font color="blue">technologies</font> in a profitable     manner, if at all</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitor</font>s or <font color="blue">others may</font> have or acquire <font color="blue">patent rights</font> that they could     enforce  against  us</td>
    </tr>
    <tr>
      <td>If  they do so, we may be required to alter our     <font color="blue">technologies</font>, pay licensing fees or cease <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">technologies</font>     conflict with <font color="blue">patent rights</font> of others, <font color="blue">third parties</font> could bring legal     <font color="blue">action against us</font> or our licensees, suppliers, customers or <font color="blue"><font color="blue">collaborator</font>s</font>,     claiming damages and seeking to enjoin <font color="blue">manufacturing</font> and marketing of the     <font color="blue">affected products</font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">legal actions</font> are successful, in addition to any     <font color="blue">potential liability</font> for damages, we might have to obtain a license in order     to continue to <font color="blue">manufacture</font> or market the <font color="blue">affected products</font></td>
    </tr>
    <tr>
      <td>A required     <font color="blue">license under</font> the related <font color="blue">patent may</font> not be <font color="blue">available on</font> acceptable terms,     if at all</td>
    </tr>
    <tr>
      <td>We may be unaware of <font color="blue">issued patents</font> that our <font color="blue">technologies</font> infringe</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>   patent <font color="blue">applications</font> can take many years to issue, there may be currently     pending <font color="blue">applications</font>, unknown to us, that may later result in <font color="blue">issued patents</font>     upon which our <font color="blue">technologies</font> may infringe</td>
    </tr>
    <tr>
      <td>There <font color="blue">could also</font> be existing     patents of which we are <font color="blue">unaware upon which</font> our <font color="blue">technologies</font> may infringe</td>
    </tr>
    <tr>
      <td>In     addition,  if <font color="blue">third parties</font> file patent <font color="blue">applications</font> or obtain patents     claiming <font color="blue">technology</font> also claimed by us in pending <font color="blue">applications</font>, we may have     to <font color="blue">participate</font> in <font color="blue"><font color="blue">interference</font> <font color="blue">proceedings</font></font> in the US Patent and Trademark     Office to determine priority of invention</td>
    </tr>
    <tr>
      <td>If <font color="blue">third parties</font> file oppositions     in  foreign  countries,  we may also have to <font color="blue">participate</font> in opposition     <font color="blue">proceedings</font> in <font color="blue">foreign tribunals</font> to defend the <font color="blue">patentability</font> of the filed     foreign patent <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>We may also have to <font color="blue">participate</font> in <font color="blue">interference</font>     <font color="blue">proceedings</font> involving our <font color="blue">issued patents</font> or our pending <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>If a third-party claims that we <font color="blue">infringe upon</font> its <font color="blue"><font color="blue">proprietary</font> rights</font>, any of     the <font color="blue">following may</font> occur:         Ø   we <font color="blue">may become involved</font> in time-consuming and expensive <font color="blue">litigation</font>, even     if the claim is <font color="blue">without merit</font>;         Ø   we <font color="blue">may become liable</font> for substantial damages for past <font color="blue">infringement</font> if a     <font color="blue">court decides</font> that our <font color="blue">technologies</font> <font color="blue">infringe upon</font> a <font color="blue">competitor</font>’s patent;         Ø   a <font color="blue">court may prohibit us from selling</font> or licensing our product without a     <font color="blue">license from</font> the patent holder, which may not be <font color="blue">available on</font> <font color="blue">commercially</font>     acceptable terms, if at all, or which may require us to pay substantial     royalties or <font color="blue">grant cross licenses</font> to our patents; and         Ø   we may have to redesign our product so that it does not <font color="blue">infringe upon</font>     others’ <font color="blue">patent rights</font>, which may not be possible or could require     substantial funds or time</td>
    </tr>
    <tr>
      <td>If any of these events occurs, our business will suffer and the <font color="blue">market price</font>     of our <font color="blue">common stock</font> will likely decline</td>
    </tr>
    <tr>
      <td>_________________________________________________________________         44      ______________________________________________________________________       Part I      _________________________________________________________________         Our rights to use <font color="blue">technologies</font> licensed to us by <font color="blue">third parties</font> are not     within our control, and we may not be able to implement our <font color="blue">products without</font>     these <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We  have  licensed  patents  and  other  rights  that are <font color="blue">necessary</font> to     <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Our business will <font color="blue">significant</font>ly suffer if these     licenses terminate, if the <font color="blue"><font color="blue">licensors</font> fail</font> to <font color="blue">abide by</font> the terms of the     license or fail to prevent <font color="blue">infringement</font> by <font color="blue">third parties</font> or if the licensed     patents or other rights are found to be invalid</td>
    </tr>
    <tr>
      <td>We have exclusively in-licensed <font color="blue">significant</font> <font color="blue">intellectual</font> property, including     patents and know-how, related to our <font color="blue"><font color="blue">cell analysis</font> instrumentation</font> and cell     isolation and <font color="blue"><font color="blue">enrichment</font> products</font></td>
    </tr>
    <tr>
      <td><font color="blue">In September </font>1999, we <font color="blue">entered into</font> a     license <font color="blue"><font color="blue">agreement</font> with</font> the University of Texas, or Texas, under which we     were <font color="blue">granted exclusive rights</font> to <font color="blue">technology</font>, including patents and know-how,     which we developed in <font color="blue">collaboration with</font> Texas, relating to the isolation,     <font color="blue">enrichment</font> and <font color="blue">characterization</font> of CTCs</td>
    </tr>
    <tr>
      <td>CTCs are cells that <font color="blue">cover external</font>     and internal body surfaces and give rise to the majority of <font color="blue">solid tumors</font></td>
    </tr>
    <tr>
      <td>This  <font color="blue">technology</font>  and  the  <font color="blue">underlying patents</font> and know-how contribute     <font color="blue">significant</font>ly  to  our  cell  <font color="blue">analysis products</font> in the field of cancer     <font color="blue"><font color="blue">diagnostic</font>s</font></td>
    </tr>
    <tr>
      <td>We are responsible for making <font color="blue">royalty payments</font> of 1prca of our     sales of <font color="blue">reagents incorporating</font> the <font color="blue">intellectual</font> property licensed to us     under this <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">agreement</font> terminates when all of Texas’s rights     to  the  licensed  <font color="blue">technologies</font>  expire</td>
    </tr>
    <tr>
      <td>In  addition, Texas also may     <font color="blue">unilaterally terminate</font> this <font color="blue">agreement</font> if we are in material breach or become     bankrupt or insolvent</td>
    </tr>
    <tr>
      <td>Texas also may <font color="blue">unilaterally terminate</font> the license     <font color="blue">granted under</font> this <font color="blue">agreement</font>, or the <font color="blue">exclusivity</font> of <font color="blue">such license</font>, in any     <font color="blue">national political jurisdiction</font> if we fail to <font color="blue">provide written evidence</font>     satisfactory to Texas, within 90 days of receiving written notice from <font color="blue">Texas     </font>that it intends to terminate this license, that we or our <font color="blue">sublicensees</font> have     <font color="blue">commercialize</font>d  or are <font color="blue">actively attempting</font> to <font color="blue">commercialize</font> a licensed     invention in these <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>In addition, in July 2002, we <font color="blue">entered into</font>     a license <font color="blue"><font color="blue">agreement</font> with</font> Streck</td>
    </tr>
    <tr>
      <td>Under this <font color="blue">agreement</font>, Streck granted to us     a non-exclusive, worldwide, royalty-bearing license to <font color="blue">practice certain</font> of     Streck’s cell preservative <font color="blue">technology</font>, including patents and know-how, for     the research, <font color="blue">development</font>, <font color="blue">manufacture</font> and sale of our CellSave Preservative     Tube to test for the presence of <font color="blue">epithelial cells</font> or CTCs in a sample of     <font color="blue">fluid from</font> a patient</td>
    </tr>
    <tr>
      <td>This <font color="blue">agreement</font> will terminate upon the <font color="blue">expiration date</font>     of the last to expire of the <font color="blue">patents licensed under</font> this <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>In     addition, either party also <font color="blue">may terminate</font> this <font color="blue">agreement</font> if the other party     is  in  material breach or <font color="blue">becomes involved</font> in financial <font color="blue"><font color="blue">difficult</font>ies</font>,     including <font color="blue">bankruptcy</font> and <font color="blue">insolvency</font></td>
    </tr>
    <tr>
      <td>If we violate the terms of our licenses, or <font color="blue">otherwise lose</font> our rights to     these  patents  or  patent  <font color="blue">applications</font>, we may be unable to continue     <font color="blue">development</font> of our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">licensors</font> or <font color="blue">others may</font> dispute the scope     of our <font color="blue">rights under</font> any of these licenses</td>
    </tr>
    <tr>
      <td>Additionally, the <font color="blue">licensors</font> under     these licenses might breach the terms of their respective <font color="blue">agreement</font>s or fail     to prevent <font color="blue">infringement</font> of the licensed patents by <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Loss of     any of these licenses for any <font color="blue">reason could materially harm</font> our financial     condition and operating results</td>
    </tr>
    <tr>
      <td>If we cannot obtain <font color="blue">additional</font> licenses to <font color="blue">intellectual</font> property owned by     <font color="blue">third parties</font> that we desire to <font color="blue">incorporate</font> into <font color="blue">new products</font> we plan to     develop,  we  may not be able to develop or <font color="blue">commercialize</font> these future     products</td>
    </tr>
    <tr>
      <td>We are developing <font color="blue">products designed</font> to identify and characterize <font color="blue">additional</font>     types of cells other than CTCs and <font color="blue">epithelial cells</font>, such as <font color="blue">endothelial</font>     cells</td>
    </tr>
    <tr>
      <td>We are also developing <font color="blue">cell profile</font> and <font color="blue">molecular products using</font>     reagents that are fluorescently tagged <font color="blue">antibodies</font> and/or probes designed to     characterize target cells, which may be <font color="blue">classified by</font> the FDA as analyte     specific  reagents, or ASRs</td>
    </tr>
    <tr>
      <td>ASRs can be used in <font color="blue">research as</font> an aid in     <font color="blue">evaluating new therapies</font> in <font color="blue">clinical trials</font>, and we plan to develop a family     of ASRs for profiling of each rare cell type of interest</td>
    </tr>
    <tr>
      <td>However, many, if     not all, of the target-specific and       _________________________________________________________________                                                                            45      ______________________________________________________________________       Part I      _________________________________________________________________         other reagents, including <font color="blue">antibodies</font> and probes, that we ultimately may use     in  the <font color="blue">development</font> and <font color="blue">commercialization</font> of these future <font color="blue">cell profile</font>     products and in our <font color="blue">future products</font> for identifying <font color="blue">additional</font> types of     <font color="blue">cells may</font> be <font color="blue">protected by patent</font> and other <font color="blue"><font color="blue">intellectual</font> property rights</font>     owned  by <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain rights to use this     third-party <font color="blue">intellectual</font> property under <font color="blue">commercially</font> reasonable terms, or at     all, we may be unable to develop these products, and this <font color="blue">could harm</font> our     ability  to  expand  our <font color="blue">commercial products offerings</font> and to generate     <font color="blue">additional</font> revenue from these products</td>
    </tr>
    <tr>
      <td>RISKS RELATING TO OUR COMMON STOCK          The <font color="blue">market price</font> of our <font color="blue">common stock</font> may be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that an <font color="blue">active trading market</font> for our <font color="blue">common stock</font> will     exist at any time</td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2005, our <font color="blue">average daily trading</font>     volume  was  <font color="blue">approximately</font>  106cmam000  shares</td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of the     27dtta5 million shares outstanding are eligible for sale in the <font color="blue">public market</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our <font color="blue">common stock</font> is likely to be <font color="blue">highly volatile</font> and     could  be subject to <font color="blue">wide <font color="blue">fluctuations</font></font> in price in response to various     factors, many of which are beyond our control, including:         Ø   actual or anticipated results of our <font color="blue">clinical trials</font>;         Ø   actual or anticipated <font color="blue"><font color="blue">regulatory</font> approvals</font> of our products or of     <font color="blue">competing products</font>;         Ø   changes in laws or <font color="blue">regulations</font> applicable to our products;         Ø   changes in the expected or <font color="blue">actual timing</font> of our <font color="blue"><font color="blue">development</font> programs</font>;         Ø   actual or anticipated <font color="blue">variations</font> in quarterly operating results;         Ø   <font color="blue">announcements</font> of <font color="blue">technological</font> <font color="blue">innovations</font> by us, our <font color="blue"><font color="blue">collaborator</font>s</font> or     our <font color="blue">competitor</font>s;         Ø   <font color="blue">new products</font> or <font color="blue">services introduced</font> or announced by us or our     <font color="blue">competitor</font>s;         Ø   changes in financial estimates or <font color="blue">recommendations by securities</font>     analysts;         Ø   <font color="blue">conditions</font> or trends in the bio<font color="blue">technology</font> and <font color="blue">pharmaceutical</font> industries;         Ø   changes in the <font color="blue">market valuations</font> of similar companies;         Ø   <font color="blue">announcements</font> by us of <font color="blue">significant</font> acquisitions, strategic partnerships,     <font color="blue">joint ventures</font> or <font color="blue">capital commitments</font>;         Ø   <font color="blue">additions</font> or <font color="blue">departures</font> of <font color="blue">key personnel</font>;         Ø   disputes or other <font color="blue">development</font>s relating to <font color="blue"><font color="blue">proprietary</font> rights</font>, including     patents, <font color="blue">litigation</font> matters and our ability to obtain <font color="blue">patent protection</font> for     our <font color="blue">technologies</font>;         Ø   the loss of a <font color="blue">collaborator</font>, including Veridex;         Ø   <font color="blue">development</font>s concerning our <font color="blue">collaborations</font>;         Ø   <font color="blue">trading volume</font> of our <font color="blue">common stock</font>; and         Ø   sales of our <font color="blue">common stock</font> by us or our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> in general, the <font color="blue">Nasdaq National Market </font>and the     market for <font color="blue">technology</font> companies in particular have experienced <font color="blue">extreme price</font>     and <font color="blue">volume <font color="blue">fluctuations</font></font> that have often been unrelated or <font color="blue">disproportionate</font>     to the operating performance of those companies</td>
    </tr>
    <tr>
      <td>Further, there has been       _________________________________________________________________         46      ______________________________________________________________________       Part I      _________________________________________________________________         <font color="blue">particular <font color="blue">volatility</font></font> in the <font color="blue">market price</font>s of securities of bio<font color="blue">technology</font>     and <font color="blue">life sciences</font> companies</td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market</font> and <font color="blue">industry factors may</font>     <font color="blue">seriously harm</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font>, regardless of our     operating performance</td>
    </tr>
    <tr>
      <td>In the past, following periods of <font color="blue">volatility</font> in the     market, securities class-action <font color="blue">litigation</font> has <font color="blue">often been instituted against</font>     companies</td>
    </tr>
    <tr>
      <td>Such <font color="blue">litigation</font>, if instituted against us, could result in     substantial costs and diversion of <font color="blue">management</font>’s attention and resources</td>
    </tr>
    <tr>
      <td>The future sale of our <font color="blue">common stock</font> and the exercise of <font color="blue">outstanding options</font>     and warrants <font color="blue">could negatively affect</font> our stock price and cause dilution</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, options to purchase 3cmam302cmam480 shares of our common     stock  and warrants to purchase 42cmam169 shares of our <font color="blue">common stock</font> were     outstanding</td>
    </tr>
    <tr>
      <td>A total of 1cmam358cmam796 of the <font color="blue">outstanding options</font> and warrants     are “in the money” and <font color="blue">exercisable as</font> of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>“In the money”     means  that  the current <font color="blue">market price</font> of the <font color="blue">common stock</font> is above the     <font color="blue">exercise price</font> of the shares subject to the warrant or option</td>
    </tr>
    <tr>
      <td>The issuance     of  <font color="blue">common stock</font> upon the exercise of these options and <font color="blue">warrants could</font>     <font color="blue">adversely</font>  affect  the  market  price of the <font color="blue">common stock</font> or result in     substantial dilution to our existing <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005     we also had restricted shares grants totaling 260cmam000 outstanding</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">grants represent outright grants</font> of our <font color="blue">common stock</font> which will vest as     follows, 160cmam000 shares in 2008 and 100cmam000 in 2009</td>
    </tr>
    <tr>
      <td>The issuance of common     <font color="blue">stock upon</font> the exercise of these options, warrants and <font color="blue">restricted common</font>     stock grants could <font color="blue"><font color="blue">adversely</font> affect</font> the <font color="blue">market price</font> of the <font color="blue">common stock</font> or     result in substantial dilution to our existing <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If the price and volume of our <font color="blue">common stock</font> experience <font color="blue">fluctuations</font>, this     could lead to costly <font color="blue">litigation</font> for us</td>
    </tr>
    <tr>
      <td>Because we have a limited operating history and operate within the medical     devices  and  <font color="blue">diagnostic</font>  products  segments of the <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font> industries, our stock price is likely to be volatile</td>
    </tr>
    <tr>
      <td>The     market  price of our <font color="blue">common stock</font> may fluctuate <font color="blue">substantially</font> due to a     variety of factors, including:         Ø   results of our <font color="blue">clinical trials</font> related to developing multiple     <font color="blue">indications</font> for our <font color="blue">cancer <font color="blue"><font color="blue">diagnostic</font> products</font></font>, such as those related to     colorectal, lung or other <font color="blue">solid tissue cancers</font>, or expanding the     <font color="blue">applications</font> of our <font color="blue">technologies</font> to fields of medicine other than cancer,     <font color="blue">such as cardiovascular</font> and <font color="blue">infectious diseases</font>;         Ø   changes in <font color="blue">reimbursement</font> policies concerning the <font color="blue"><font color="blue">diagnostic</font> products</font>     that we or our <font color="blue">competitor</font>s offer;         Ø   media reports and <font color="blue">publications</font> and <font color="blue">announcements</font> about cancer or     <font color="blue"><font color="blue">diagnostic</font> products</font> or <font color="blue">new cancer treatments</font> or <font color="blue">innovations</font> that could     <font color="blue">compete with</font> our products;         Ø   <font color="blue">announcements</font> concerning our <font color="blue">competitor</font>s or the <font color="blue">medical devices</font> and     <font color="blue"><font color="blue">diagnostic</font> products</font> segments in general;         Ø   new <font color="blue">regulatory</font> pronouncements, changes in <font color="blue">regulatory</font> guidelines, such as     adverse changes in <font color="blue">reimbursement</font> for <font color="blue">cancer <font color="blue"><font color="blue">diagnostic</font> products</font></font>, and timing     of <font color="blue"><font color="blue">regulatory</font> approvals</font> concerning the products in our pipeline;         Ø   market <font color="blue">conditions</font> or trends related to the medical <font color="blue"><font color="blue">diagnostic</font>s</font> and     bio<font color="blue">technology</font> industries or the market in general;         Ø   <font color="blue">additions</font> to or <font color="blue">departures</font> of our <font color="blue">key personnel</font>, in particular, the loss     of, Byron D Hewett, our President and Chief Executive Officer, Leon WMM     Terstappen, our Chief Scientific Officer, and James G Murphy, our Chief     Financial Officer;       _________________________________________________________________                                                                            47      ______________________________________________________________________       Part I      _________________________________________________________________         Ø   disputes or other <font color="blue">development</font>s relating to <font color="blue"><font color="blue">proprietary</font> rights</font>, including     patents, <font color="blue">litigation</font> matters and our ability to obtain <font color="blue">patent protection</font> for     our <font color="blue">technologies</font>;         Ø   changes in financial estimates or <font color="blue">recommendations by securities</font>     analysts;         Ø   <font color="blue">variations</font> in our <font color="blue">quarterly financial</font> and operating results; and         Ø   changes in <font color="blue">accounting principles</font></td>
    </tr>
    <tr>
      <td>The  market  prices  of the securities of bio<font color="blue">technology</font> and <font color="blue">diagnostic</font>     companies, <font color="blue">particularly</font> companies like <font color="blue">ours without consistent product</font>     revenues and earnings, have been <font color="blue">highly volatile</font> and are likely to remain     <font color="blue">highly volatile</font> in the future</td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has often been unrelated to     the operating performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">market price</font>s     for stocks of bio<font color="blue">technology</font>-related companies, <font color="blue">particularly</font> following an     initial public offering, frequently reach levels that bear no <font color="blue">relationship</font>     to  the  operating performance of these companies</td>
    </tr>
    <tr>
      <td>These <font color="blue">market price</font>s     <font color="blue">generally</font>  are  not  sustainable and are <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>In the past,     companies that experience <font color="blue">volatility</font> in the <font color="blue">market price</font> of their securities     have  often  faced  securities class action <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Whether or not     <font color="blue">meritorious</font>, <font color="blue">litigation</font> <font color="blue">brought against us</font> could result in substantial     costs, divert our <font color="blue">management</font>’s attention and resources and harm our ability     to grow our business</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws and     under  <font color="blue">Delaware  </font>law  <font color="blue">could inhibit</font> a change in control or a change in     <font color="blue">management</font> that holders of our <font color="blue">common stock</font> consider favorable</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>in our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws could delay or     prevent a change of control or change in <font color="blue">management</font> that would provide     holders of our <font color="blue">common stock</font> with a premium to the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>These provisions include those:         Ø   <font color="blue">authorizing</font> the <font color="blue">issuance without further approval</font> of “<font color="blue">blank check</font>”     <font color="blue">preferred stock</font> that could be issued by our board of <font color="blue">directors</font> to increase     the number of <font color="blue">outstanding shares</font> and thwart a <font color="blue">takeover attempt</font>;         Ø   <font color="blue">prohibiting cumulative voting</font> in the election of <font color="blue">directors</font>, which would     <font color="blue">otherwise allow less than</font> a majority of <font color="blue">stockholders</font> to <font color="blue">elect director</font>     <font color="blue">candidates</font>;         Ø   limiting the ability to remove <font color="blue">directors</font>;         Ø   limiting the ability of <font color="blue">stockholders</font> to <font color="blue">call special meetings</font> of     <font color="blue">stockholders</font>;         Ø   prohibiting stockholder action by written consent, thereby requiring all     <font color="blue">stockholder actions</font> to be taken at a meeting of <font color="blue">stockholders</font>; and         Ø   <font color="blue">establishing</font> advance notice <font color="blue">requirements</font> for <font color="blue">nominations</font> for election to     the board of <font color="blue">directors</font> or for <font color="blue">proposing matters</font> that can be acted upon by     <font color="blue">stockholders</font> at stockholder meetings</td>
    </tr>
    <tr>
      <td>In addition, Section 203 of the <font color="blue">General Corporation Law of the State </font>of     Delaware,  as  amended, or the <font color="blue">Delaware General Corporation Law </font>limits     business combination transactions with 15 percent <font color="blue">stockholders</font> that have not     been <font color="blue">approved by</font> our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>These provisions and <font color="blue">others could</font>     make it <font color="blue">difficult</font> for a third-party to acquire us, or for members of our     board of <font color="blue">directors</font> to be replaced, even if doing so would be <font color="blue">beneficial</font> to     our  <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>our board of <font color="blue">directors</font> is responsible for     appointing the members of our <font color="blue">management</font> team, these <font color="blue">provisions could</font> in     turn affect any attempt to replace the current <font color="blue">management</font> team</td>
    </tr>
    <tr>
      <td>If a change     of control or change in <font color="blue">management</font> is delayed or prevented, holders of our     <font color="blue">common stock</font> may lose an <font color="blue">opportunity</font> to realize a premium on their shares of     <font color="blue">common stock</font> or the <font color="blue">market price</font> of our <font color="blue">common stock</font> could decline</td>
    </tr>
    <tr>
      <td>_________________________________________________________________         48      ______________________________________________________________________       Part I      _________________________________________________________________         We do not expect to <font color="blue">pay dividends</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>As a result,     holders of our <font color="blue">common stock</font> must rely on stock <font color="blue">appreciation</font> for any return     on their <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We  do not anticipate <font color="blue">paying cash dividends on</font> our <font color="blue">common stock</font> in the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Certain of our existing credit <font color="blue">agreement</font>s prohibit the     payment  of cash dividends without lender consent</td>
    </tr>
    <tr>
      <td>Any payment of cash     dividends  will  also  depend  on  our <font color="blue">financial condition</font>, results of     <font color="blue">operations</font>,  capital <font color="blue">requirements</font> and other factors and will be at the     <font color="blue">discretion</font> of our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Accordingly, holders of our common     stock will have to rely on capital <font color="blue">appreciation</font>, if any, to earn a return on     their <font color="blue">investment</font> in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Furthermore, we may in the future     become subject to contractual <font color="blue">restrictions</font> on, or <font color="blue">prohibitions against</font>, the     payment of dividends</td>
    </tr>
  </tbody>
</table>